Therefore, considering the unmet need of treatment for this orphan disease, we set out to test the therapeutic potential of GLP-1R agonists not only in WFS1-deficient mice, but also in human WFS1-deficient beta cells and neurons, and in a humanised mouse model of Wolfram syndrome. This evidence concerns the gene GLP1R and Wolfram syndrome.